Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 08.02.2024
Verbio SE
Q2 2023/24: Verbio holds its own in a volatile market environment
Solid Q2 2023/24 performance despite expansion costs and difficult market conditions
Operational excellence: new record levels of production in 1 HY 2023/24 achieved
Leipzig, February 8, 2024 – Verbio continues on its growth path in the first half of 2023/24, with production volu [ … ]
Thu, 08.02.2024
Travelex Issuerco 2 Plc
Travelex Issuerco 2 Plc
Results for Q4 2023
Travelex Issuerco 2 Plc
8 February 2024
Travelex Issuerco 2 Plc ("Travelex" or the "Company")
8 February 2024
Results for Q4 2023 ("Q4 Results")
The Company's Q4 Results are accessible via the following link:
http://www.rns-pdf.londonstockexchange.com/rns/4019C_1-2024-2-7.pdf
Enquiries:
Tr [ … ]
Thu, 08.02.2024
Nordea Bank Abp
Nordea Bank Abp
/ Key word(s): Transaction in Own Shares
Transaction in Own Shares
08.02.2024 / 08:00 CET/CEST
Nordea Bank Abp: Repurchase of own shares on 07.02.2024
Nordea Bank Abp
Stock exchange release - Changes in company's own shares
07.02.2024 at 22.30 EET
Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 07.0 [ … ]
Thu, 08.02.2024
Bastei Lübbe AG
Bastei Lübbe confirms higher forecast with strong nine-month figures
Group revenues in the first nine months of the 2023/2024 financial year increased by 15.3 percent over the previous year to €84.4 million (previous year: €73.2 million)
Significant increase in Group EBIT to €11.7 million (previous year: €4.8 million) in tandem with substant [ … ]
Thu, 08.02.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 8, 2024
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Transaction is part of S [ … ]
Thu, 08.02.2024
Crealogix Holding AG
Following the end of the additional acceptance period, VENCORA UK Limited has published the provisional notice of the end result of its public tender offer for all publicly held registered shares in CREALOGIX Holding AG with a nominal value of CHF 8.00 each. The provisional notice of the end result shows that, based on preliminary figures, 662,422 [ … ]
Thu, 08.02.2024
Nemetschek SE
Corporate News
Successful finish to the year: Nemetschek Group clearly achieves its already raised targets for the financial year 2023
+8.0% revenue growth (constant currency) to a new record high of EUR 851.6 million
EBITDA margin at a high 30.3%
+26.7% growth in Annual Recurring Revenue (ARR) to EUR 718.6 million
Share of recurring revenues [ … ]
Thu, 08.02.2024
Swiss Prime Site AG
Ad Hoc announcement pursuant to article 53 LRPRESS RELEASEZug, 8. February 2024
Increase in rental income, up by 4.3% (EPRA LfL) to CHF 438 million and reduction in vacancies to record low of 4.0%
Increase in operating results (FFO I) per share by +1.3% to CHF 4.05
Increase in real estate assets under management to CHF 21.5 billion – CHF 13.1 bi [ … ]
Thu, 08.02.2024
WashTec AG
WashTec AG preliminary figures for 2023:
Expected revenue of €490m higher than prior year (€482m)
Expected EBIT of €42m significantly higher than prior year (€38m); EBIT margin: 9% (prior year: 8%)
Augsburg, February 8, 2024: The WashTec Group has announced that, on preliminary figures, it successfully concluded fiscal year 2023 with an expected [ … ]
Thu, 08.02.2024
Leonteq AG
PRESS RELEASE | LEONTEQ PUBLISHES FULL-YEAR 2023 RESULTS
Zurich, 8 February 2024 | Ad hoc announcement pursuant to Art. 53 LR
Leonteq AG (SIX: LEON) reports Group net profit of CHF 20.6 million for the full-year 2023 as net fee income was relatively stable supported by a solid client franchise, while net trading result significantly decreased due [ … ]